Germany rejoices at record pharma R&D investment, but regulations still bite
This article was originally published in SRA
Executive Summary
Germany’s research-based pharmaceutical industry has enjoyed record levels of investment in research and development (R&D) in 2007. “The figures show that the research-based pharmaceutical companies place great faith in Germany as a haven for pharmaceutical research,” said Cornelia Yzer, Director General of the German Association of Research-Based Pharmaceutical Companies (VFA).